Clinical Trials at Duke Comprehensive Cancer Center

If you need additional information about any of the trials listed or would like to inquire about other open trials, please contact:

GASTROINTESTINAL (GI Team)
Contacts:Anthony Amara, Wanda Honeycutt, RN or Nancy Lee, RN
Phone:(919) 668-1861
Email:giclintrials@duke.edu
 
GASTROINTESTINAL ENDOCRINE (Neuro-endocrine)
Contacts:Shawna Savage, RN or Liz Anderson, RN
Phone:(919) 684-6342
Email:giclintrials@duke.edu
Trial Phase Gastrointestinal Cancers - Colorectal cancers and cancers of the stomach, esophagus and other digestive organs
00005437 III CTSU ECOG 5202 A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value
00007054 I/II A Phase 1b/2 Study to Evaluate the Safety and Efficacy of AMG 655 or AMG 479 in Combination with Gemcitabine as First-Line Therapy for Metastatic Pancreatic Cancer
00007293 II A Multicenter, Randomized, Blinded Efficacy and Safety Study of Pasireotide LAR vs Octreotide LAR in Patients with Metastatic Carcinoid Tumors Whose Disease-related Symptoms are Inadequately Controlled by Somatostatin Analogues
00010959 I/II A Phase I Open Label/ Phase II Randomized, Double-Blind, Multicenter Study Investigating the Combination of RAD001 and Sorafenib (Nexavar) in Patients With Locally Advanced Hepatocellular Carcinoma
00011744 III A Multinational, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AVE5026 in the Prevention of Venous Thromboembolism (VTE) in Cancer Patients at High Risk for VTE and Who are Undergoing Chemotherapy
00013018 I A Phase 1b, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Multiple Doses of Apo2L/TRAIL Administered Intravenously in Combination with Camptosar/Erbitux Chemotherapy in Subjects with Previously Treated Metastatic Colorectal Cance
00008012 II A Phase II Open Label Study of Brivanib (BMS-582664), Administered Orally At A Dose of 800 mg Daily in Subjects with Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regi
00008710 II A Phase II Study of Oxaliplatin, Capecitabine and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarciomas
00010354 I/II A Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and Dasatinib for Patients with Advanced Solid Tumors with Expanded Cohort of Patients with Previously Untreated Metastatic Colorectal Cancer.
00001497 III A Randomized, Double Blind, Placebo-Controlled, Multicenter Phase III Study in Patients with Advanced Carcinoid Tumor Receiving Sandostatin LAR and RAD001 10 mg/d or Sandostatin LAR and placebo
00001597 I/II A Phase I/II Trial of Radiation, Avastin and Tarceva for Resectable or Locally Advanced Pancreatic Adenocarcinoma
00003414 IV A Phase IV Study of the Pharmacokinetics of Oral Posaconazole (SCH 56592) Among Patients with Compromised Gastrointestinal Function and at High Risk for Invasive Fungal Infection
00009042 IV A Treatment Protocol for Patients Continuing from a Prior SU011248 Protocol
00012976 I A Phase I Study of the Combinations of Gemcitabine plus Dasatinib or Gemcitabine, Cetuximab, and Dasatinib in Patients with Refractory Solid Tumors with Expansion to the First-Line Treatment of Advanced Pancreatic Cancer
Duke Comprehensive Cancer Center Accolades